Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity

Challenges and strategies for developing efficacious and long-lasting malaria vaccines

(2019) James G. Beeson et al.   Science Translational Medicine

Low Levels of Human Antibodies to Gametocyte-Infected Erythrocytes Contrasts the PfEMP1-Dominant Response to Asexual Stages in P. falciparum Malaria

(2019) Jo-Anne Chan et al.   Frontiers in Immunology

Identification of domains within Pfs230 that elicit transmission blocking antibody responses

(2019) Mayumi Tachibana et al.   VACCINE

Establishment of a yeast-based VLP platform for antigen presentation

(2018) David Wetzel et al.   Microbial Cell Factories

Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults

(2018) Issaka Sagara et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults

(2018) Jessica A. Chichester et al.   VACCINE

Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of thePlasmodium falciparumSexual Stage Protein Pfs230

(2016) Nicholas J. MacDonald et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antibody responses to surface antigens ofPlasmodium falciparumgametocyte-infected erythrocytes and their relation to gametocytaemia

(2016) B. Dinko et al.   PARASITE IMMUNOLOGY

Naturally acquired immunity to sexual stage P. falciparum parasites

(2016) WILL J. R. STONE et al.   PARASITOLOGY

Transmission-blocking activity is determined by transmission-reducing activity and number of control oocysts in Plasmodium falciparum standard membrane-feeding assay

(2016) Kazutoyo Miura et al.   VACCINE

Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults

(2016) Kawsar R. Talaat et al.   PLoS One

Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization

(2016) Karl D. Brune et al.   Scientific Reports

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

(2015)   LANCET

Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

(2015) Michael T White et al.   LANCET INFECTIOUS DISEASES

Quantification of female and male Plasmodium falciparum gametocytes by reverse transcriptase quantitative PCR

(2015) Petra Schneider et al.   MOLECULAR AND BIOCHEMICAL PARASITOLOGY

Recent advances in recombinant protein-based malaria vaccines

(2015) Simon J. Draper et al.   VACCINE

Transmission blocking malaria vaccines: Assays and candidates in clinical development

(2015) R.W. Sauerwein et al.   VACCINE

Qualification of Standard Membrane-Feeding Assay with Plasmodium falciparum Malaria and Potential Improvements for Future Assays

(2013) Kazutoyo Miura et al.   PLoS One

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Cutting Edge: Limited Specialization of Dendritic Cell Subsets for MHC Class II-Associated Presentation of Viral Particles

(2009) Susanne A. Keller et al.   JOURNAL OF IMMUNOLOGY

Wheat Germ Cell-Free System-Based Production of Malaria Proteins for Discovery of Novel Vaccine Candidates

(2008) T. Tsuboi et al.   INFECTION AND IMMUNITY

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51

(2008) Yimin Wu et al.   PLoS One